Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.51 |
| ▸ | CSF1R | P07333 | 4/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | WEE1 | P30291 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995151 | 0.85 | BRD4 (0.48) | CDK4CSF1RCDK6NPC1RAB9A | |
| SCHEMBL18994991 | 0.83 | NPC1 (0.47) | CDK4CSF1RCDK6NPC1RAB9A | |
| SCHEMBL18995043 | 0.82 | TBK1 (0.55) | JAK2TBK1 | |
| SCHEMBL19527758 | 0.82 | NPC1 (0.46) | CDK4CSF1RCDK6NPC1RAB9A | |
| SCHEMBL15320920 | 0.75 | CSF1R (0.43) | CDK4CSF1RCDK6PAK1EGFR | |
| SCHEMBL17708214 | 0.75 | CSF1R (0.43) | CDK4CSF1RCDK6PAK1EGFR | |
| SCHEMBL3955783 | 0.75 | AXL (0.59) | CSF1RPAK1EGFRAXLSLC2A1 | |
| SCHEMBL19527678 | 0.73 | NPC1 (0.47) | NPC1RAB9AEGFRGRM5 | |
| SCHEMBL22164969 | 0.73 | CDK4 (0.65) | CDK4CSF1RCDK6PAK1FLT3 | |
| SCHEMBL2483649 | 0.73 | SLC2A1 (0.63) | CDK4CSF1RNPC1RAB9APAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | CDK4 968/4885CSF1R 4551/4885CDK6 319/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | CDK4 968/4885CSF1R 4551/4885CDK6 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.